X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Allegra-D (fexofenadine) is an over-the-counter oral antihistamine and nasal decongestant for the temporary relief of nasal and sinus congestion due to colds or allergies.
Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Allegra-D
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2022
Details:
LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).
Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area: Immunology Product Name: Diregura
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: LTL Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
Results from a recent pilot study showed that SJP-001, comprising a combination of naproxen and fexofenadine was significantly more effective in reducing alcohol hangover severity than placebo.
Lead Product(s): Naproxen,Fexofenadine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SJP-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. -Adelia leadership bring extensive clinical and commercialization experience of major drugs, including Allegra, Sabril, Anzemet , and Vaniqa.
Lead Product(s): Fexofenadine Hydrochloride
Therapeutic Area: Immunology Product Name: Allegra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CYBIN
Deal Size: $15.75 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
